These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20302183)

  • 1. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
    Derer W; Dechend R; Müller DN
    MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARAs to the RESCUE.
    Kaplan NM
    J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypertension, angiotensin II, aldosterone, and race.
    Ben-Yehuda O
    J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 8. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 9. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone receptor antagonists for heart failure: current status, future indications.
    Pitt B; Rajagopalan S
    Cleve Clin J Med; 2006 Mar; 73(3):257-60, 264-8. PubMed ID: 16548448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonists.
    Parthasarathy HK; MacDonald TM
    Curr Hypertens Rep; 2007 Mar; 9(1):45-52. PubMed ID: 17362671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.